financetom
Business
financetom
/
Business
/
Cascades Reports Q4 Sales Beat and Higher Adjusted EPS
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Cascades Reports Q4 Sales Beat and Higher Adjusted EPS
Feb 20, 2025 5:07 AM

07:36 AM EST, 02/20/2025 (MT Newswires) -- Cascades (CAS.TO) on Thursday, reported a fourth-quarter sales beat and an increase in adjusted earnings per share as favourable average selling prices and raw material costs in the containerboard business drove stronger sequential results, offsetting the impact of lower seasonal volumes.

The company reported an increase in adjusted net earnings for the three-months ended Dec. 31, to $25 million compared with $5 million in the prior year period. Adjusted net earnings per common share was $0.25 compared with $0.05 in the previous year but missed analyst forecasts polled by FactSet of $0.29.

Sales rose to $1.21 billion in Q4 from $1.14 billion a year earlier, beating analyst expectations of $1.19 billion.

Cascades Chief Executive Hugues Simon commented: "Broadly, the depreciation of the Canadian dollar benefited quarterly results, but led to higher reported debt levels at the end of the year given the company's $1.3 billion of US denominated debts."

Simon added that raw material costs remain a tailwind in the first quarter. Cascades said it would not provide near-term financial outlook given the uncertainties regarding the implementation of bilateral tariffs between Canada and the United States.

The company also added that about 11% of its annual sales were derived from finished products made in Canada and sold to U.S. customers. "Cross-border inter-company transfers, and raw material sourcing increases this potential annual exposure to tariffs to about 15% of revenues." However, Cascades said it had started proactive steps to mitigate these impacts.

The board declared a quarterly dividend of $0.12 per common share, unchanged from the prior quarter, to be paid on March 20 to shareholders of record at the close of business on March 6.

Shares of the company closed down $0.06, or 0.5%, at $12.80 on Wednesday on the Toronto Stock Exchange.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Trulieve Cannabis Reports Insider Share Purchases Reflecting
Trulieve Cannabis Reports Insider Share Purchases Reflecting "Confidence" in Co; Also Opening Medical Cannabis Dispensary in Jacksonville, Florida
Nov 22, 2024
08:45 AM EST, 11/22/2024 (MT Newswires) -- Trulieve Cannabis ( TCNNF ) said Friday that several members of its executive management team and board of directors recently made purchases of the company's subordinate voting shares. Trulieve said the purchases reflect their confidence in the company's growth potential and direction. Between Nov. 8 and Nov. 21, certain executives including Chairman and...
Verizon Communications Reports Progress on Tender Offers
Verizon Communications Reports Progress on Tender Offers
Nov 22, 2024
08:45 AM EST, 11/22/2024 (MT Newswires) -- Verizon Communications ( VZ ) said Friday it has tendered 38.1% or $490.9 million of the $1.29 billion in 3.376% notes due 2025, effective Thursday. It said it also tendered $373.0 million, or 42.7% of $873.9 million of floating rate notes due 2025, and $252.8 million, or 51.3%, of $493.1 million floating rate...
Halozyme withdraws $2.1 bln buyout offer for Evotec
Halozyme withdraws $2.1 bln buyout offer for Evotec
Nov 22, 2024
Nov 22 (Reuters) - Halozyme Therapeutics ( HALO ) said on Friday it had withdrawn its proposal to acquire Evotec SE for 2 billion euros ($2.09 billion) after the German drug developer was unwilling to engage in discussions. ($1 = 0.9587 euros) (Reporting by Sriparna Roy in Bengaluru; Editing by Devika Syamnath) ...
Johnson & Johnson Applies for FDA Approval of Tremfya Subcutaneous Induction Regimen for Ulcerative Colitis
Johnson & Johnson Applies for FDA Approval of Tremfya Subcutaneous Induction Regimen for Ulcerative Colitis
Nov 22, 2024
08:47 AM EST, 11/22/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Friday it has applied to the US Food and Drug Administration seeking approval of a subcutaneous induction regimen of Tremfya to treat adults with moderately to severely active ulcerative colitis. The company said its supplemental biologics license application, or SBLA, is based on phase 3 study...
Copyright 2023-2026 - www.financetom.com All Rights Reserved